The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7951826 B1

PDF
Full Text
Expired
Date of Patent:
May. 31, 2011

Filed:

Mar. 13, 2006
Applicants:

Lisa Selsam Beavers, Franklin, IN (US);

Don Richard Finley, Greenwood, IN (US);

Robert Alan Gadski, Indianapolis, IN (US);

Philip Arthur Hipskind, New Palestine, IN (US);

Cynthia Darshini Jesudason, Indianapolis, IN (US);

Richard Todd Pickard, Noblesville, IN (US);

Freddie Craig Stevens, Indianapolis, IN (US);

Takako Takakuwa, Indianapolis, IN (US);

Inventors:

Lisa Selsam Beavers, Franklin, IN (US);

Don Richard Finley, Greenwood, IN (US);

Robert Alan Gadski, Indianapolis, IN (US);

Philip Arthur Hipskind, New Palestine, IN (US);

Cynthia Darshini Jesudason, Indianapolis, IN (US);

Richard Todd Pickard, Noblesville, IN (US);

Freddie Craig Stevens, Indianapolis, IN (US);

Takako Takakuwa, Indianapolis, IN (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 31/4025 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.


Find Patent Forward Citations

Beavers, Lisa. (2011). Pyrrolidine derivatives as histamine h3 receptor antagonists (U.S. Patent No. 7951826). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/7951826

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…